Formoterol is a frequently prescribed β 2 -agonist used for the treatment of asthma. Due to performance enhancing effects of some β 2 -agonists, formoterol appears on the prohibited list, published by the World Anti-doping Agency (WADA). Its therapeutic use is allowed but restricted to inhalation. Since the data on urinary concentrations originating from therapeutic use is limited, no discrimination can be made between use and misuse when a routine sample is found to contain formoterol. Therefore the urinary excretion of 6 volunteers after inhalation of 18 µg of formoterol was investigated.
Introduction
Formoterol is a potent long-acting β 2 -adrenergic agonist and has a pronounced and very effective bronchodilating effect [1] . Consequently, it is amongst the most prescribed drugs for humans in the treatment of asthma. Besides the desired pharmacological action ,some β 2 -agonists produce side-effects on protein synthesis and lipolysis resulting in anabolic action at higher doses [2] . Hence β 2 -agonists might be misused in sports for the stimulatory effects on the respiratory and central nervous system and for growth-promoting action. To control the use of β 2 -agonists, the World Anti Doping Agency (WADA) included them in the list of prohibited substances [3] and imposed a minimum required performance level (MRPL) of 100 ng/mL [4] .
Before the introduction of liquid-chromatography mass spectrometry (LC-MS), the detection of β 2 -agonists in the field of doping analysis was performed by gas chromatography-mass spectrometry (GC-MS) [5] . For formoterol N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) in combination with trimethylsilyl-imidazole (TMSIm) is the preferred choice to derivatize all groups including the nitrogen of the β-ethanolamine chain [6] . Monitoring formoterol in our laboratory by GC-MS after basic liquid-liquid extraction and derivatisation never resulted in an adverse analytical finding (AAF) for this substance. Liquid chromatography-mass spectrometry (LC-MS) has proven to be an effective tool in the urinary detection of β 2 -agonists related to doping control analysis [7] [8] [9] [10] . Its application for β 2 -agonist-detection in our laboratory since 2007, resulted in numerous urine samples which were found to contain formoterol (non published results).
Because of therapeutic importance, the use of formoterol is widespread and the current (2011) situation is that the athlete should have a therapeutic use exemption (TUE). Consequently, formoterol is frequently declared on doping control forms [11] . Because the information on urinary concentrations of formoterol after inhalation is limited to one paper describing an administration study with 2 volunteers [5] , it is difficult to assign the detected concentrations in the routine samples to therapeutic use or to doping misuse. Therefore, the objective of this study was to investigate the urinary excretion of a therapeutic dose of formoterol after inhalation. Additionally, concentrations from the excretion study will be compared with those observed in routine samples. The scan speed and scan width were maintained at 100 ms and 0.01 amu, respectively. The 32 collision gas pressure was 1.5 mTorr. The internal standard (IS)-solution (50 µL, 100 ng/mL of formoterol-d 6 in MeOH) was added to 37 1 mL of urine, followed by the addition of 1 mL of acetate buffer (pH 5.2) and 50 µl of the 38 enzyme solution. After 2.5h of incubation at 56°C, 1 mL of carbonate buffer (pH 9.5) was added. A six-point calibration curve was generated by spiking blank urine with methanolic formoterol 49 solutions in triplicate at 0.5, 1, 5, 10, 25 and 50 ng/mL. The ratio's of target compound product 50 ion area to IS product ion were plotted versus concentration to obtain calibration curves.
Experimental

51
Precision and bias were tested at the lowest, middle and highest calibrator. Precision was 52 assessed as the percentage relative standard deviation (%RSD) of both repeatability (within-day) 53 (n=6) and reproducibility (between-day and different analysts) (n=18) for a selected level.
54
Maximum allowed tolerances for precision can be calculated from the Horwitz-equation RSD max 55 = 2
(1-0.5logC) (C = concentration (µg/mL) x 10 -6 ). Maximum allowed tolerances for repeatability 56 and reproducibility were 2/3 RSD max and RSD max , respectively [12] . Bias was defined as the 57 difference between the calculated mean amount and the specified amount as a percentage [13] .
58
The limit of quantification (LOQ) of the method was defined as the lowest concentration where 59 precision and bias were within the above mentioned criteria. Using a least square fit, good linearity (r 2 ≥ 0.98) was observed. The calibration curve was not 115 forced through the origin and for the regression calculation a weighing factor of 1/x was used for 116 all data points.
117
The results for precision and bias are summarised in Table 2 (LOQ) of the method was 0.5 ng/mL.
122
Regarding the selectivity, interferences from other monitored doping agents could not be found. to a previous study where salmeterol was monitored [8] . Indeed, formoterol is the most popular 166 β 2 -agonist used for the treatment of exercise induced asthma.
167
The histogram showing the distribution of the detected concentrations is presented in figure 5 .
168
The highest detected concentration was 20.8 ng/mL whereas in the excretion study the maximum 169 observed concentration was 11.4 ng/mL ( Figure 6 ).
170
The concentrations obtained in our study are obtained after a normal day dose of 2 inhalations. 
